Cannabis Company, Organigram, Reports An Impressive Q3 Turnaround

The Company is pleased with its positive adjusted EBITDA Q3 results and, with $173 million in pro-forma cash believes they have one of the strongest balance sheets in the industry and are well positioned to capitalize on future growth opportunities.